Last updated: August 12, 2026
GSK Biologicals is one of the world’s largest vaccine businesses, with competitive strength concentrated in adult immunization, respiratory vaccines, meningococcal products, and global pediatric franchises. GSK’s leading products include Shingrix, Arexvy, Boostrix, Bexsero, Engerix-B, Fluarix and Priorix. Its commercial position is strongest in vaccines with high clinical value, complex manufacturing requirements and limited near-term substitution.
GSK’s main strategic risks are concentrated in the aging Shingrix franchise, declining pandemic-era vaccine demand, intense competition in respiratory syncytial virus, or RSV, vaccines, and pricing pressure from governments and institutional purchasers. The company’s patent estate supports market protection, but regulatory exclusivity, manufacturing complexity, adjuvant know-how, brand recognition and procurement access are at least as important as individual patent terms.
What is GSK Biologicals and how large is its vaccine business?
GSK Biologicals is the vaccine operating business of GSK plc, headquartered in Belgium and commercially active across North America, Europe, Asia-Pacific and emerging markets. GSK reports vaccines as one of its two principal operating segments, alongside specialty medicines and general medicines.
| Metric |
Recent position |
| GSK total 2024 sales |
Approximately £31.4 billion |
| GSK vaccines sales in 2024 |
Approximately £9.1 billion |
| Shingrix 2024 sales |
Approximately £4 billion-plus |
| Core vaccine categories |
Adult, pediatric, respiratory, meningococcal and travel vaccines |
| Principal markets |
United States, Europe, Japan and major emerging markets |
| Primary competitors |
Merck, Sanofi, Pfizer, Moderna, CSL Seqirus and Bavarian Nordic |
Source: GSK, 2024 full-year results and annual reporting materials.[1]
GSK has a differentiated position because it combines a large adult vaccine franchise with established pediatric and meningococcal products. Merck is the strongest direct competitor in shingles through Gardasil’s broader vaccine platform and its large pediatric and oncology businesses, while Sanofi has greater scale in pediatric vaccines and influenza. Pfizer and Moderna are more concentrated in respiratory and mRNA-based products.
Which vaccines drive GSK Biologicals’ market position?
Shingrix
Shingrix is GSK’s most important vaccine franchise. It is a recombinant, adjuvanted vaccine for prevention of herpes zoster and postherpetic neuralgia in adults. The U.S. Food and Drug Administration approved Shingrix in 2017, and the product has since expanded across major markets.
Shingrix benefits from:
- High efficacy in adults aged 50 and older.
- Strong recommendations from public-health authorities.
- Use in immunocompromised adults.
- A two-dose schedule that creates recurring demand.
- Significant manufacturing and adjuvant-development barriers.
Merck’s Zostavax was withdrawn from the U.S. market in 2020, leaving Shingrix with a dominant U.S. shingles position. The principal long-term competitive threat is not a conventional generic launch. It is substitution by future shingles vaccines, improved delivery technologies or competing products from large vaccine manufacturers.
Arexvy
Arexvy was the first FDA-approved RSV vaccine for adults aged 60 and older. The FDA approved it in May 2023, and the label was later expanded to include adults aged 50 through 59 who are at increased risk of RSV lower respiratory tract disease.[2]
Arexvy competes with Pfizer’s Abrysvo and Moderna’s mResvia. The commercial market is still developing, and uptake depends on:
- Advisory Committee on Immunization Practices recommendations.
- Seasonal vaccination behavior.
- Payer reimbursement.
- Public-health guidance on revaccination.
- Comparative effectiveness and safety data.
- Contracting with pharmacies and health systems.
GSK’s RSV position is strategically important because it protects the company from relying solely on Shingrix. It also exposes GSK to a market with substantial uncertainty over annual demand, coadministration, pricing and competitive differentiation.
Bexsero and meningococcal vaccines
Bexsero is a meningococcal group B vaccine used in adolescents and young adults and in certain high-risk populations. It competes with Pfizer’s Trumenba. Bexsero has established public-health and institutional demand, but its market is more dependent on country-specific immunization schedules than Shingrix.
Boostrix
Boostrix is a Tdap vaccine used for protection against tetanus, diphtheria and pertussis. Its demand comes from adolescent vaccination, pregnancy vaccination and adult booster programs. The product has a mature market profile and faces greater price and procurement pressure than newer specialty vaccines.
Pediatric and travel vaccines
GSK sells Engerix-B for hepatitis B, Havrix for hepatitis A, Priorix for measles, mumps and rubella, and other pediatric and travel vaccines. These products create geographic breadth and manufacturing scale. They also carry lower growth rates than Shingrix and Arexvy.
How does GSK compare with Merck, Sanofi, Pfizer and Moderna?
| Company |
Principal vaccine strength |
Competitive position versus GSK |
| GSK |
Shingrix, RSV, meningococcal, pediatric and adult vaccines |
Strongest adult-vaccine concentration |
| Merck |
Gardasil, MMR, pneumococcal and pediatric vaccines |
Major scale competitor; strongest in HPV |
| Sanofi |
Influenza, pediatric, travel and RSV vaccines |
Broadest traditional vaccine portfolio |
| Pfizer |
Pneumococcal, meningococcal and RSV vaccines |
Strong respiratory and hospital presence |
| Moderna |
mRNA COVID-19 and RSV vaccines |
Technology-driven respiratory challenger |
| CSL Seqirus |
Influenza and selected specialty vaccines |
Strong influenza procurement position |
| Bavarian Nordic |
Mpox, smallpox and travel vaccines |
Specialized public-health portfolio |
GSK’s key advantage is portfolio balance between established products and high-value adult vaccines. Merck has greater exposure to HPV through Gardasil, while Sanofi has a broader historical position in pediatric immunization and influenza. Moderna has greater platform flexibility but less commercial breadth outside mRNA respiratory vaccines.
What patents protect GSK Biologicals’ major vaccines?
GSK’s vaccine protection is generally built from layered rights covering antigen design, recombinant proteins, adjuvant systems, formulation, dosage regimens, manufacturing processes and therapeutic use. The relevant protection may include patents owned by GSK, patents licensed from research institutions, and regulatory exclusivity.
For Shingrix, the principal technical protection relates to the recombinant varicella-zoster virus glycoprotein E antigen and the AS01 adjuvant system. AS01 includes monophosphoryl lipid A and QS-21 in a liposomal formulation. The product’s protection is therefore broader than a single active-ingredient patent.
For Arexvy, protection is associated with the prefusion F protein antigen, adjuvant formulation, dosing and use in older or high-risk adults. Competitors may avoid direct infringement by using a different antigen construct, adjuvant or administration schedule.
GSK’s patent risk should be assessed across four layers:
| Layer |
Typical protected subject matter |
Business relevance |
| Antigen |
Recombinant proteins, antigen variants and conformations |
Protects the biological target |
| Adjuvant |
AS01 components, combinations and delivery systems |
Creates technical differentiation |
| Formulation |
Stabilizers, ratios, excipients and containers |
Supports product consistency and shelf life |
| Use and dosing |
Age groups, schedules and immunocompromised populations |
Supports label-based enforcement |
Patent expiration dates vary by country and by patent family. Regulatory exclusivity periods also differ from patent terms. The United States generally provides 12 years of reference-product exclusivity for licensed biologics, although vaccines can have overlapping patent, regulatory and manufacturing protection. Product-specific freedom-to-operate conclusions require review of issued claims, terminal disclaimers, patent-term adjustment, patent-term extension and post-grant proceedings.
What is the Orange Book and Purple Book status of GSK vaccines?
Most GSK vaccines are biological products and are not listed in the FDA Orange Book in the same manner as conventional small-molecule prescription drugs. Their relevant U.S. reference-product and biosimilar information is generally associated with the FDA Purple Book.[3]
This distinction affects generic-entry analysis:
- A conventional ANDA pathway is generally not the primary route for a complex vaccine.
- A biosimilar or interchangeable designation may be legally available for some biological products, but a vaccine competitor must still demonstrate a highly comparable product.
- Vaccine-specific manufacturing, analytical characterization, clinical immunogenicity and facility requirements can make substitution difficult.
- Public-health recommendations and procurement contracts may matter more than automatic pharmacy substitution.
Shingrix and Arexvy therefore should not be analyzed as ordinary Orange Book small molecules. Their competitive exposure is more likely to arise from competing biologics, new vaccines, public tenders and label-based patent disputes.
When do GSK vaccine franchises lose exclusivity?
There is no single loss-of-exclusivity date for a GSK vaccine. The commercial protection period depends on the interaction of patent expiry, regulatory exclusivity, manufacturing know-how and market adoption.
| Product |
FDA milestone |
Principal exclusivity issue |
Likely entry mechanism |
| Shingrix |
Approved 2017 |
Layered antigen, adjuvant, formulation and use rights |
Competing vaccine or follow-on biologic |
| Arexvy |
Approved 2023 |
New biologic exclusivity plus platform and formulation patents |
Competing RSV vaccine |
| Bexsero |
Approved 2015 |
Mature product and formulation estate |
Competing MenB vaccine |
| Boostrix |
Approved 2005 |
Mature biologic and manufacturing estate |
Institutional substitution |
| Engerix-B |
Approved 1989 |
Mature vaccine franchise |
Competing hepatitis B products |
| Priorix |
Approved in multiple non-U.S. markets |
Mature pediatric vaccine protection |
Public procurement and substitution |
Exact patent expiry dates must be determined at the patent-family and jurisdiction level. A product’s commercial exclusivity can continue after a primary patent expires if competitors cannot reproduce the antigen, adjuvant, quality profile or manufacturing process at scale.
Are Paragraph IV challenges relevant to GSK vaccines?
Paragraph IV litigation is most relevant to small-molecule products listed in the Orange Book. It is generally less central to vaccines and other biologics, which use different FDA approval and patent-certification mechanisms.
For GSK’s major vaccines, the likely dispute patterns are:
- Patent infringement actions against competing biologics.
- Declaratory-judgment litigation before commercial launch.
- Patent challenges involving adjuvant composition or antigen design.
- Inter partes review or post-grant review of issued U.S. patents.
- European opposition proceedings before the European Patent Office.
- Contract and licensing disputes concerning manufacturing technology.
A conventional abbreviated generic launch is not the base case for Shingrix or Arexvy. A competitor is more likely to develop a distinct vaccine construct and challenge market share through separate regulatory approval.
What formulation patents and manufacturing barriers protect GSK vaccines?
Formulation and manufacturing rights are central to GSK’s vaccine position. Important barriers include:
- Adjuvant particle size and composition.
- Liposomal delivery systems.
- Antigen-adjuvant ratios.
- Protein expression and purification.
- Cold-chain stability.
- Fill-finish validation.
- Sterility assurance.
- Batch consistency.
- Potency and immunogenicity testing.
- Large-scale supply of specialized raw materials.
For Shingrix, AS01 manufacturing and supply of QS-21-related materials are particularly important. For recombinant vaccines, the ability to produce consistent antigen conformations at commercial scale may be more difficult to replicate than the broad biological concept itself.
Manufacturing know-how is not fully disclosed in patent documents. Trade secrets, process controls, regulatory history and validated facilities can extend practical protection beyond the expiration of individual patents.
Which companies are challenging GSK in RSV and adult vaccines?
GSK faces direct RSV competition from Pfizer and Moderna. Sanofi also competes in RSV through its antibody-based product Beyfortus, developed with AstraZeneca, which targets infants rather than the same adult vaccine segment.
The competitive landscape is divided by population:
| Segment |
GSK product |
Main competitors |
| Older adults, RSV |
Arexvy |
Pfizer Abrysvo, Moderna mResvia |
| Infants, RSV prevention |
No direct GSK lead product comparable to Beyfortus |
Sanofi/AstraZeneca |
| Shingles |
Shingrix |
Future vaccines; Zostavax withdrawn in U.S. |
| MenB |
Bexsero |
Pfizer Trumenba |
| HPV |
No leading GSK product |
Merck Gardasil |
| Influenza |
Fluarix |
Sanofi, CSL Seqirus, AstraZeneca |
The most important near-term competitive variable is RSV vaccine demand. The market may support multiple products, but pricing and uptake will be sensitive to comparative effectiveness, duration of protection and recommendations for repeat vaccination.
What litigation and settlement risks affect GSK Biologicals?
GSK’s vaccine business can face patent litigation, product-liability claims, manufacturing disputes, procurement challenges and regulatory actions. The litigation profile differs from a conventional pharmaceutical company because vaccine disputes often involve:
- Product liability and alleged adverse events.
- Manufacturing quality and contamination claims.
- Patent disputes over platform technologies.
- Licensing obligations for adjuvants and antigen technology.
- Government contracting and supply commitments.
- Antitrust or market-access allegations.
Publicly visible litigation should be reviewed through GSK annual reports, SEC filings, FDA records, court dockets and patent-office databases. No single public litigation proceeding currently defines the entire GSK vaccine investment case. Settlement agreements may delay competitor entry, but they do not carry the same predictable commercial role as branded-generic settlements under the Hatch-Waxman framework.
How strong is the GSK Biologicals patent estate?
GSK’s estate is strongest where patents are combined with regulatory complexity and manufacturing know-how. Shingrix has the most strategically important protection because its value depends on the interaction of antigen, adjuvant and dosing. Arexvy has a newer estate but faces a more competitive market.
| Strength factor |
Shingrix |
Arexvy |
Mature GSK vaccines |
| Product differentiation |
High |
Moderate to high |
Moderate |
| Patent layering |
High |
High |
Variable |
| Manufacturing complexity |
High |
High |
Moderate to high |
| Substitution risk |
Moderate |
High |
High |
| Regulatory exclusivity |
Strong |
Strong |
Largely mature |
| Near-term revenue exposure |
Very high |
High growth potential |
Stable but lower growth |
The principal weakness is concentration. Shingrix has become a major revenue contributor, so any decline in adult vaccination rates, payer coverage or product perception would have an outsized effect on GSK’s vaccine segment.
What licensing deals support GSK’s vaccine portfolio?
GSK’s vaccine portfolio has historically relied on external innovation, academic collaboration and technology licensing. The AS01 adjuvant system reflects licensed and partnered technology, including rights associated with QS-21-related adjuvant components. GSK also has a longstanding collaboration with the U.S. government and other public-health institutions across vaccine development, supply and procurement programs.
Licensing analysis should focus on:
- Royalty obligations tied to adjuvant technology.
- Geographic scope of licensed rights.
- Sublicensing provisions.
- Ownership of improvements.
- Manufacturing rights.
- Change-of-control provisions.
- Milestone and supply obligations.
A licensed platform can improve product differentiation while reducing control over cost of goods and patent strategy.
What generic launch scenarios exist for GSK vaccines?
The most plausible entry scenarios are:
Scenario 1: Direct competing vaccine
A rival develops a different antigen or adjuvant and obtains an independent license. This is the principal threat to Shingrix and Arexvy.
Scenario 2: Follow-on biologic or biosimilar
A company seeks approval using a biologics pathway. This is technically and commercially difficult for complex vaccines and may not produce automatic substitution.
Scenario 3: Public-tender displacement
A competitor wins national or regional procurement contracts through lower price, supply reliability or broader portfolio terms. This is more relevant to mature pediatric, influenza and travel vaccines.
Scenario 4: New technology substitution
An mRNA, viral-vector or improved protein vaccine offers easier manufacturing, broader coverage or a more convenient dosing schedule.
Scenario 5: Patent-only challenge
A competitor challenges specific formulation or method-of-use claims while retaining a distinct product design. This could reduce litigation exposure without eliminating GSK’s market position.
What is the revenue exposure of GSK’s vaccine business?
GSK’s vaccine segment generates roughly one-third of group revenue, making it a central contributor to corporate performance.[1] Shingrix is the largest individual exposure. Arexvy provides growth potential but also adds volatility because RSV vaccine uptake remains less mature than shingles vaccination.
The business has three financial characteristics:
- High gross-value products can offset slower mature-franchise growth.
- Public procurement creates volume but can compress price.
- Manufacturing interruptions can affect revenue rapidly because vaccine inventory and seasonal demand are tightly linked.
GSK’s strategic objective is to extend adult immunization beyond shingles into RSV and other age-related diseases while maintaining pediatric and meningococcal scale.
Key Takeaways
- GSK Biologicals is a top-tier global vaccine company with particular strength in adult immunization.
- Shingrix is the core commercial asset and the largest source of franchise concentration.
- Arexvy gives GSK a major position in the emerging adult RSV market but faces Pfizer and Moderna competition.
- Vaccine exclusivity depends on patents, biologics regulation, manufacturing know-how and procurement access.
- Orange Book Paragraph IV analysis is less relevant than Purple Book, biologics and independent vaccine approval pathways.
- Formulation and adjuvant technology, especially AS01-related know-how, materially strengthen GSK’s competitive position.
- The largest generic-entry risk is replacement by a competing vaccine, not an automatic pharmacy-substitutable generic.
- GSK’s main strategic risks are adult-vaccine demand volatility, RSV price competition, manufacturing constraints and revenue concentration in Shingrix.
FAQs About GSK Biologicals’ Competitive Landscape
Does GSK Biologicals have a biosimilar threat?
Yes, but the immediate threat is limited. Complex vaccines require extensive analytical, manufacturing and clinical work, and follow-on products may not receive automatic substitution. Independent competing vaccines are a more realistic threat.
Is Shingrix protected by one patent or several patents?
Shingrix is protected by a layered estate involving antigen, adjuvant, formulation, dosing and manufacturing-related rights. Commercial protection does not depend on one patent alone.
Is Arexvy stronger than Pfizer’s Abrysvo?
Neither product has an established permanent market advantage. Competition depends on effectiveness, safety, recommendations, revaccination policy, payer coverage and supply.
Can a generic company launch Shingrix after a patent expires?
A conventional generic launch is unlikely to be sufficient. A competitor would generally need to develop and obtain approval for a comparable biological vaccine or an independently designed alternative.
What GSK vaccine has the greatest long-term commercial risk?
Shingrix has the greatest revenue concentration risk because it is a major franchise and the shingles market may mature before GSK’s next adult-vaccine products fully replace its growth contribution.
References
- GSK plc. (2025). Annual report 2024 and full-year results. GSK plc.
- U.S. Food and Drug Administration. (2024). AREXVY prescribing information. FDA.
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products. FDA.
